Everything below concerns Visceral adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Sandra Jill James is a retired American biochemist and autism researcher who studied metabolic autism biomarkers. She worked at Arkansas Children's Hospital Research Institute, where she was the director of the Metabolic Genomics Laboratory, as well as the University of Arkansas for Medical Sciences' department of pediatrics, where she began working in 2002. She was also a member of the Autism Speaks Treatment Advisory Board. James' research focused on the role of epigenetics in autism, as well as the effectiveness of supplements as a treatment for autism and the potential existence of abnormal metabolism in autistic children. This research was previously funded by a 5-year grant from the National Institutes of Health entitled "Metabolic biomarkers of autism: predictive potential and genetic susceptibility", as well as by a grant from Autism Speaks. James has falsely speculated that the thiomersal used as a preservative in some vaccines is potentially harmful to the human brain and that prophylactic supplements may protect against such harm preceding vaccination.
The hydrogen bond criterion for beta turns, applied to polypeptides whose amino acids are linked by trans peptide bonds, gives rise to just four categories, as shown by Venkatachalam in 1968. They are called types I, II, I' and II'. All occur regularly in proteins and polypeptides but type I is most common, because it most resembles an alpha helix, occurring within 310 helices and at the ends of some classic alpha helices. Type II beta turns, on the other hand, often occur in association with beta-sheet as part of beta-links. The four types of beta turn are distinguished by the φ, ψ angles of residues i+1 and i+2 as shown in the table below giving the typical average values. Glycines are especially common as amino acids with positive φ angles; for prolines such a conformation is sterically impossible but they occur frequently at amino acid positions where φ is negative.
== Personal life == In the early 1990s, Staley enrolled in several rehab programs, but he failed to stay clean for long. At one point, the other members of Alice in Chains flew to Los Angeles for weekly therapy at Staley's rehab. During the Dirt tour, Alice in Chains' manager, Susan Silver, hired bodyguards to keep Staley away from people who might try to pass him drugs, but he ended up relapsing on alcohol and drugs during the tour. Screaming Trees' Mark Lanegan recalled partying with Staley on tour and said that, "off stage, it was an insane, dark, drug and alcohol-fuelled frat party from start to finish, with Layne [Staley] and I raising hell, behaving like teenagers, staying up for days on end. We partook of whatever drugs came our way. Heroin, cocaine, painkillers, anything." Kurt Cobain's death in April 1994 scared Staley into temporary sobriety, but soon he was back into his addiction. Alice in Chains' managers turned down lucrative touring possibilities and kept the band off the road, hoping that would help Staley. Pearl Jam lead guitarist Mike McCready also tried to help Staley by inviting him to his side project, Mad Season. McCready had hoped that playing with sober musicians would encourage Staley. On October 29, 1996, Staley's former fiancée, Demri Lara Parrott, died of a drug overdose. Staley was placed on a 24-hour suicide watch, according to NME, which quoted a friend saying Staley was taking Parrott's death "extremely badly" and had fallen into a deep depression. Lanegan told Rolling Stone in 2002, "He never recovered from Demri's death.
Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus Solanum, such as the potato (Solanum tuberosum). It can occur naturally in any part of the plant, including the leaves, fruit, and tubers. Solanine has pesticidal properties, and it is one of the plant's natural defenses. Solanine was first isolated in 1820 from the berries of the European black nightshade (Solanum nigrum), after which it was named. It belongs to the chemical family of saponins.
Sources: en.wikipedia.org
== Discovery == Since the 1960s, seryl-tRNA synthetases have been described in various eukaryotic species, in both biochemical and structural analyses. It was not until 1997 that human SARS and its enzyme product were isolated and expressed in Escherichia coli by a team from The European Molecular Biology Laboratory in France.
Dinoflagellates are the primary source of dinosteral. Dinoflagellates are unicellular, aquatic organisms that live in both marine and inland environments and are a prominent constituent of phytoplankton. Dinoflagellates are often characterized by their uncommon sterol distribution, dominated by 4α-methyl sterols derived from lanosterol rather than cycloartenol. In many cases, the most abundant sterol in dinoflagellates is dinosterol. Dinosterol is often used a biomarker in geochemical research because it is produced almost exclusively by dinoflagellates and is found in many environments. In addition to several species of dinoflagellates, dinosterol has also been isolated from the diatom Nivicula sp. (CS-46c) collected from Port Hacking, New South Wales, Australia.
Ralph William James Rimmer. Lately Chief Executive Officer, Rugby Football League. For services to Rugby League Football. Dr. Lisa Margaret Ritchie. Head of Infection Prevention and Control, NHS England. For services to Healthcare, particularly during Covid-19. Michael Thomas Robinson. Chief Executive, Royal Scottish Geographical Society. For services to Climate Change Education. Professor Colva Mary Roney-Dougal. Professor of Mathematics, University of St Andrews. For services to Education and Mathematics. Kenneth James Gordon Harvey Ross. Founding Officer, National Down Syndrome Policy Group. For services to Charity, to Education and to People with Down Syndrome. Diane Rosalie Aldworth Ruddock. For services to the Environment, to Heritage and to the community in Northern Ireland. John Hamilton Ryley. Lately Head of News, Sky News. For services to Journalism. Clovis Constantine Salmon. Documentary Filmmaker. For services to Culture and to the Black Community. William Henry Salomon. President, Young Enterprise. For services to Education. Carolyn Margaret Sampson. Soprano. For services to Music. Steven Ross Savory. Chief Executive Officer, Gloucestershire Learning Alliance. For services to Education. Professor Ulrike Hermine Schmidt. Professor of Eating Disorders, King's College London and Consultant Psychiatrist, South London and Maudsley NHS Foundation Trust. For services to People with Eating Disorders. Ian Charles Sears. Commercial Specialist, Cabinet Office. For Public Service. Ruth Victoria Shaw. Chief Executive Officer, Premier League Charitable Fund.
=== Author === While known within the fandom for his spoken storytelling, Conway is also the author of several short stories published in various works by Sofawolf Press. In May 1998, Conway was invited to write a story based on his interest in birds of prey, particularly the red-tailed hawk. The result was "Tweaked in the Head", published December 1999 in Flights of Fantasy. He next contributed to the first issue of HistoriMorphs, a fanzine mixing historical fiction with interaction between humans and anthropomorphic animals. "The Secret of Wollknäul" took place in Nazi Germany at the end of World War II, and was published in June 2001. He went on to write "The Good Bird of Nanking" and "It Takes A Fox" for subsequent issues of the series. For Anthrolations #5—a magazine of dramatic fiction—Conway submitted "Six", a previously-written work "based on a true story" involving wildlife rehabilitation from his days as a Red Cross volunteer. The story, illustrated by Synnabar, was nominated for "Best Anthropomorphic Short Story" in the 2002 Ursa Major Awards. Also nominated that year was Breaking the Ice: Stories from New Tibet, a collection set in and around a subarctic mining colony; Conway's contribution, "Dead End", features a bartending vulture who provides an introduction to the harsh, dystopic world.
=== Absorption === The oral bioavailability of CPA is 68 to 100%. The absorption of oral CPA is slow but complete, and the medication is not subject to a significant first-pass effect. The mean absorption half-life of oral CPA is about 1.5 hours. Steady-state levels of CPA occur with oral CPA after about 8 days of continuous administration, with a 2- to 3-fold gradual accumulation in CPA levels. Oral CPA is taken daily and intramuscular CPA is administered weekly or biweekly. Following a single low oral dose of 2 mg CPA in combination with 35 or 50 μg ethinylestradiol in premenopausal women, mean peak levels of CPA of 7.2 to 15.2 ng/mL (17–36.5 nmol/L) have been recorded after 1.6 to 3.7 hours. In healthy men, a single high oral dose of 100 mg CPA produced maximal CPA levels of 254 ng/mL (609 nmol/L) after 2.6 hours. In aged men with prostate cancer, continuous oral CPA therapy resulted in CPA levels of 132 ± 18 ng/mL at 25 mg/day, 246 ± 13 ng/mL at 50 mg/day, and 348 ± 23 ng/mL at 100 mg/day. Similarly, in healthy young women, a single high oral dose of 100 mg CPA resulted in peak CPA levels of 255 ng/mL (612 nmol/L) within 2 to 3 hours. During continuous treatment with high oral doses of CPA in women with hirsutism, levels of CPA were 199 to 228 ng/mL (477–547 nmol/L) with 50 mg/day CPA and were 436 to 520 ng/mL (1050–1250 nmol/L) with 100 mg/day CPA. After a single intramuscular injection of 300 mg CPA in healthy young women, maximal levels of CPA of 191 ng/mL (458 nmol/L) and of 15β-OH-CPA of 164 ng/mL occurred after 2 to 4 days.
Sources: en.wikipedia.org
The Kenny Report on Sky News Australia Sky News on Sky News Australia Today on the Nine Network 7.30 on ABC TV Sunrise on Seven Network The Project on Network 10 A Current Affair on Nine Network Q+A on ABC TV ABC News on ABC News In 2021 he starred in television adverts on behalf of the Australian government about COVID-19 vaccinations. In 2023 Coatsworth filled in as presenter of Today while regular host Karl Stefanovic took Christmas leave. His appointment left "plenty of noses out of joint" due to his perceived inexperience.
Directed assembly of micro- and nano-structures are methods of mass-producing micro to nano devices and materials. Directed assembly allows the accurate control of assembly of micro and nano particles to form even the most intricate and highly functional devices or materials.
=== Relationship with the Federation === Federalism is one of the entrenched constitutional principles of Germany. Accordingly, the states form a considerable counterweight to the power of the federation. In principle, the power to enact laws lies with the states; the federation can only enact its own laws if the Basic Law explicitly assigns it legislative powers in the respective area. This can be done in two ways:
== Research directions == Current research and recommendations to manage severe acute malnutrition (SAM), such as kwashiorkor, in children, are largely based on expert opinions. Only one-third of the WHO guidelines for the management of SAM are based on epidemiological and clinical research. Further studies are needed to "improve treatment outcomes in the large number of children with SAM."
=== Serotonin precursors === The serotonin precursors tryptophan and 5-hydroxytryptophan (5-HTP; oxitriptan) are available as over-the-counter supplements. They are often used to produce sleepiness and treat insomnia. However, little to no clinical data exist to support their use or effectiveness.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.